Omentoo-D Capsule is a combination pharmaceutical formulation containing Domperidone 10 mg and Omeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The combined action of these agents in Omentoo-D Capsule offers both symptomatic relief and addresses underlying pathophysiological mechanisms in acid-peptic disorders. It is indicated for patients experiencing dyspepsia with associated delayed gastric emptying and acid reflux symptoms. Omentoo-D should be administered as prescribed by a healthcare professional, with caution advised in patients with known hypersensitivity to either component, significant hepatic impairment, or cardiac arrhythmias. Common adverse effects may include headache, dry mouth, or abdominal discomfort. This combination therapy enhances patient compliance by reducing pill burden and optimizing therapeutic outcomes in gastrointestinal management.